{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:50:37Z","timestamp":1789537837082,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41371-020-0377-6","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T13:04:07Z","timestamp":1594645447000},"page":"148-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease"],"prefix":"10.1038","volume":"35","author":[{"given":"Ningning","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asadur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-820X","authenticated-orcid":false,"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"377_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10157-018-1567-1","volume":"22","author":"A Nishiyama","year":"2018","unstructured":"Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018;22:1231\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"377_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293\u2013300.","journal-title":"Hypertens Res"},{"key":"377_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/JOE-11-0372","volume":"213","author":"PJ Fuller","year":"2012","unstructured":"Fuller PJ, Yao Y, Yang J, Young MJ. Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol. 2012;213:15\u201324.","journal-title":"J Endocrinol"},{"key":"377_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"377_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrcardio.2009.244","volume":"7","author":"JL Samuel","year":"2010","unstructured":"Samuel JL, Delcayre C. Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol. 2010;7:125\u20137.","journal-title":"Nat Rev Cardiol"},{"key":"377_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316.","journal-title":"Am J Hypertens"},{"key":"377_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","volume":"188","author":"D Vukadinovic","year":"2017","unstructured":"Vukadinovic D, Lavall D, Vukadinovic AN, Pitt B, Wagenpfeil S, Bohm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99\u2013108.","journal-title":"Am Heart J"},{"key":"377_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385\u2013403.","journal-title":"ChemMedChem"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"377_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ejhf.444","volume":"18","author":"P Bramlage","year":"2016","unstructured":"Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18:28\u201337.","journal-title":"Eur J Heart Fail"},{"key":"377_CR11","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine. 2018;97:e0254.","journal-title":"Medicine"},{"key":"377_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"377_CR13","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1021\/jm300806c","volume":"55","author":"DW Piotrowski","year":"2012","unstructured":"Piotrowski DW. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem. 2012;55:7957\u201366.","journal-title":"J Med Chem"},{"key":"377_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: first global approval. Drugs. 2019;79:477\u201381.","journal-title":"Drugs"},{"key":"377_CR15","doi-asserted-by":"publisher","unstructured":"Takahashi M, Ubukata O, Homma T, Asoh Y, Honzumi M, Hayashi N, et al. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Lett. 2020. https:\/\/doi.org\/10.1002\/1873-3468.13746.","DOI":"10.1002\/1873-3468.13746"},{"key":"377_CR16","doi-asserted-by":"publisher","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE. 2018;13:e0193380.","journal-title":"PLoS ONE"},{"key":"377_CR17","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47:1090\u2013103.","journal-title":"Xenobiotica"},{"key":"377_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2019","unstructured":"Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, metabolism, and excretion of [(14)C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47:340\u20139.","journal-title":"Drug Metab Dispos"},{"key":"377_CR19","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s12325-019-00956-z","volume":"36","author":"A Kurata","year":"2019","unstructured":"Kurata A, Furuie H, Ishizuka T, Nakatsu T, Shimizu T, Kato M, et al. Absolute bioavailability of esaxerenone and food effects on its pharmacokinetics after a single oral dose in healthy japanese subjects: an open-label crossover study. Adv Ther. 2019;36:1618\u201327.","journal-title":"Adv Ther"},{"key":"377_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"},{"key":"377_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"377_CR22","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"377_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"14","author":"S Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14:1161\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"377_CR24","doi-asserted-by":"publisher","unstructured":"Kurata A, Yoshida T, Inoue M, Ishizuka T, Nakatsu T, Shimizu T, et al. Pharmacokinetics and safety of single-dose esaxerenone in japanese subjects with mild to moderate hepatic impairment. Adv Ther. 2019. https:\/\/doi.org\/10.1007\/s12325-019-01121-2.","DOI":"10.1007\/s12325-019-01121-2"},{"key":"377_CR25","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"377_CR26","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512\u20138.","journal-title":"Circulation"},{"key":"377_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"377_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","volume":"42","author":"L Li","year":"2019","unstructured":"Li L, Guan Y, Kobori H, Morishita A, Kobara H, Masaki T, et al. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res. 2019;42:769\u201378.","journal-title":"Hypertens Res"},{"key":"377_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"377_CR30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42:892\u2013902.","journal-title":"Hypertens Res"},{"key":"377_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fendo.2019.00584","volume":"10","author":"S Gorini","year":"2019","unstructured":"Gorini S, Kim SK, Infante M, Mammi C, La Vignera S, Fabbri A, et al. Role of aldosterone and mineralocorticoid receptor in cardiovascular aging. Front Endocrinol. 2019;10:584.","journal-title":"Front Endocrinol"},{"key":"377_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/ijms18051032","volume":"18","author":"JW Funder","year":"2017","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors-497 physiology and pathophysiology. Int J Mol Sci. 2017;18:1032.","journal-title":"Int J Mol Sci."},{"key":"377_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","volume":"47","author":"N Kobayashi","year":"2006","unstructured":"Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47:671\u20139.","journal-title":"Hypertension"},{"key":"377_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"377_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Hoft B, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67:402\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"key":"377_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"377_CR37","doi-asserted-by":"publisher","first-page":"e920615","DOI":"10.12659\/AJCR.920615","volume":"21","author":"K Okamura","year":"2020","unstructured":"Okamura K, Matsushima M, Yamamoto F, Takamiya Y, Okuda T, Shirai K, et al. A patient with bilateral primary aldosteronism refractory to oral eplerenone who responded to esaxerenone with increased renin activity. Am J Case Rep. 2020;21:e920615.","journal-title":"Am J Case Rep"},{"key":"377_CR38","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125\u2013t140.","journal-title":"J Endocrinol"},{"key":"377_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78\u201385.","journal-title":"Curr Opin Pharmacol"},{"key":"377_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jpainsymman.2016.12.320","volume":"53","author":"L Carone","year":"2017","unstructured":"Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Spironolactone. J Pain Symptom Manag. 2017;53:288\u201392.","journal-title":"J Pain Symptom Manag"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0377-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0377-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-0377-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:25:28Z","timestamp":1684603528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-0377-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-0377-6","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AN has received speaking honoraria from Taisho, Tanabe-Mitsubishi, Boehringer Ingelheim, Daiichi-Sankyo, and has received research funds from Daiichi-Sankyo, Boehringer Ingelheim, Bayer and Taisho. The funders had no role in the preparation of this paper. This study was also supported in part by the Salt Sciences Foundation (to AN).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}